Skip to main content
TipRanks
Go Ultimate75% OFF

BLIS Technologies Limited (BLT) AI Stock Analysis

0 Followers
NZ:BLT

BLIS Technologies Limited

(NZX:BLT)

Select Model
Rating:60Neutral
Price Target:NZD 0.03â–²(4.17% Upside)
Action:initiatedcoverage
Date:10/05/26

The score is driven primarily by improving financial performance and strong revenue momentum, supported by a conservatively levered balance sheet. The biggest offsets are weakened FY2026 cash flow (negative operating and free cash flow) and compressed margins, while the stock also appears overbought technically and carries a high P/E that increases downside sensitivity if execution slips.

Positive Factors
Accelerating Revenue GrowthThe step-up in revenue demonstrates stronger commercial momentum for BLT’s probiotic oral-health products and partner ingredients. Continued top-line expansion can improve operating leverage, support broader market reach, and provide a stronger base for rebuilding profitability over the next several quarters.
Negative Factors
Sharp Margin CompressionThe steep decline in gross margin materially weakens earnings quality and leaves limited operating profit from each dollar of sales. Unless margins recover or costs are controlled, future revenue growth may translate into only modest earnings, making performance more sensitive to product mix and execution.

BLIS Technologies Limited (BLT) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%NZ:BLT+60.00%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
NZD 31.34M
Dividend Yield
―
Average Volume (3M)
448.75K
Price to Earnings (P/E)
48.0
Beta (1Y)
0.49
Revenue Growth
16.01%
EPS Growth
-28.57%
Country
NZ
Employees
43
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

BLIS Technologies Limited Business Overview & Revenue Model

Company Description

BLIS Technologies Limited, together with its subsidiaries, specializes in creating and distributing health-focused products. These offerings are underpinned by unique bacterial strains that exhibit bacteriocin activity. The company prominently featur...

BLIS Technologies Limited Financial Statement Overview

Summary

Revenue growth has accelerated strongly through FY2026 and the company has returned to positive net income. Offsetting this, FY2026 shows sharp margin compression (gross margin down to ~43% and EBIT margin ~4%) and a deterioration in cash generation with negative operating cash flow and free cash flow, raising near-term execution and funding-risk concerns despite low leverage.

Income Statement

68Positive

Balance Sheet

82Very Positive

Cash Flow

44Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue14.67M14.67M11.56M10.48M9.96M8.80M
Gross Profit6.40M6.25M9.01M8.23M7.77M6.87M
EBITDA1.09M1.08M1.49M1.25M-746.00K-2.02M
Net Income692.00K692.00K838.00K646.00K-1.35M-2.71M
Balance Sheet
Total Assets14.97M14.97M14.30M12.93M12.81M14.14M
Cash, Cash Equivalents and Short-Term Investments8.51M8.51M9.73M8.60M8.35M8.59M
Total Debt439.00K439.00K589.00K389.00K619.00K754.00K
Total Liabilities1.93M1.93M1.97M1.45M1.97M1.99M
Stockholders Equity13.04M13.04M12.32M11.49M10.84M12.15M
Cash Flow
Free Cash Flow-720.00K-720.00K1.31M486.00K9,000-2.57M
Operating Cash Flow-595.00K-595.00K1.79M1.05M106.00K-2.31M
Investing Cash Flow451.00K451.00K-1.68M-819.00K-4.10M-262.00K
Financing Cash Flow-147.00K-147.00K-217.00K-224.00K-275.00K8.92M

BLIS Technologies Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.02

Price Trends

50DMA0.02Negative
100DMA0.02Negative
200DMA0.02Negative

Market Momentum

MACD-0.00Positive
RSI40.16Neutral
STOCH-200.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:BLT, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 40.16 is Neutral, neither overbought nor oversold. The STOCH value of -200.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NZ:BLT.

BLIS Technologies Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NZ:BLT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NZ:PHLNZ:PHL63NeutralNZD 33.62M0.03――15.19%1154.17%
NZ:BLTNZ:BLT60NeutralNZD 31.98M48.00――16.01%-28.57%
NZ:TAHNZ:TAH58NeutralNZD 37.83M11.70―4.15%21.56%18.96%
NZ:RADNZ:RAD56NeutralNZD 113.39M10.18―6.03%9.76%-1.75%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NZ:RUANZ:RUA42NeutralNZD 11.77M-2.60――70.82%41.04%

* Healthcare Sector Average

Performance Comparison

0%50%NZ:BLTNZ:PHLNZ:TAHNZ:RADNZ:RUADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NZ:BLT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NZ:BLTBLIS Technologies Limited0.020.0160.00%
NZ:PHLPromisia Healthcare Limited0.620.0611.71%
NZ:TAHThird Age Health Services Limited3.86-1.74-31.12%
NZ:RADRadius Residential Care Ltd0.400.024.99%
NZ:RUARua Bioscience Ltd.0.03-0.00-3.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 05, 2026